Clinical Trial Update: A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating necitumumab in combination with gemcitabine-cisplatin for malignant solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumor

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Necitumumab (necitumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Malignant Solid Tumor | Phase 2 | Status: COMPLETED | Results posted: 2016-08-26